Antibody drugs have reshaped how we treat diseases. By harnessing the immune system to destroy tumours or temper excessive inflammation in autoimmune disorders, these therapeutics have become ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

A retrospective case series identified nine patients who developed ophthalmic complications during treatment with semaglutide ...

The nonclinical pharmacokinetic (PK) and pharmacodynamic (PD) study was conducted to examine the effects of semaglutide ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Low-density lipoproteins (LDL) -- commonly known as bad cholesterol -- have long been on scientists' radar as a major contributor to heart disease. But these microscopic troublemakers have hidden ...

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes.

Low-density lipoproteins (LDL) - commonly known as bad cholesterol - have long been on scientists' radar as a major contributor to heart disease.

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Low-density lipoproteins (LDL) - commonly known as bad cholesterol - have long been on scientists' radar as a major ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...